Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company’s all-human monoclonal antibodies target and neutralize human immunodeficiency virus and are being employed to produce anti-SARS-CoV-2 monoclonal antibodies for treating COVID-19. Its proprietary therapeutic is also being tested against Hepatitis A, B and C, Rheumatoid Arthritis, certain forms of cancer, rabies, influenza A and B, tetanus, and diphtheria. The company was founded on July 28, 2004 and is headquartered in Allen, TX.